Quince Therapeutics Inc banner

Quince Therapeutics Inc
NASDAQ:QNCX

Watchlist Manager
Quince Therapeutics Inc Logo
Quince Therapeutics Inc
NASDAQ:QNCX
Watchlist
Price: 0.08 USD -8.78% Market Closed
Market Cap: $4.5m

Balance Sheet

Balance Sheet Decomposition
Quince Therapeutics Inc

Balance Sheet
Quince Therapeutics Inc

Rotate your device to view
Balance Sheet
Currency: USD
Dec-2017 Dec-2018 Dec-2019 Dec-2020 Dec-2021 Dec-2022 Dec-2023 Dec-2024
Assets
Cash & Cash Equivalents
7
23
50
52
56
15
6
6
Cash
7
11
4
36
40
4
2
3
Cash Equivalents
0
12
46
16
16
11
4
4
Short-Term Investments
0
49
50
82
51
75
69
35
Other Current Assets
0
1
6
4
5
4
2
3
Total Current Assets
8
73
106
138
112
94
77
44
PP&E Net
0
0
1
1
1
1
1
1
PP&E Gross
0
0
1
1
1
1
1
1
Accumulated Depreciation
0
0
0
1
1
0
1
1
Intangible Assets
0
0
0
0
0
6
64
60
Goodwill
0
0
0
0
0
0
18
0
Note Receivable
0
0
0
0
0
0
0
5
Long-Term Investments
0
0
17
51
20
4
0
0
Other Long-Term Assets
0
0
0
0
0
0
8
4
Other Assets
0
0
0
0
0
0
18
0
Total Assets
8
N/A
73
+847%
124
+71%
190
+52%
133
-30%
104
-22%
168
+62%
114
-32%
Liabilities
Accounts Payable
1
1
3
4
5
1
2
3
Accrued Liabilities
1
1
6
13
9
2
3
4
Short-Term Debt
0
0
0
0
0
0
0
0
Current Portion of Long-Term Debt
0
0
0
0
0
0
0
0
Other Current Liabilities
0
0
0
0
0
0
4
0
Total Current Liabilities
2
2
9
17
14
3
10
7
Long-Term Debt
7
0
0
0
0
0
13
14
Deferred Income Tax
0
0
0
0
0
0
5
5
Other Liabilities
2
0
0
0
0
0
55
58
Total Liabilities
11
N/A
2
-86%
9
+493%
17
+93%
15
-15%
3
-77%
83
+2 410%
84
+2%
Equity
Common Stock
17
104
0
0
0
0
0
0
Retained Earnings
20
33
70
147
237
288
320
376
Additional Paid In Capital
0
0
185
319
355
389
402
407
Other Equity
0
0
0
0
0
0
3
0
Total Equity
3
N/A
71
N/A
116
+62%
172
+49%
119
-31%
101
-15%
85
-15%
30
-65%
Total Liabilities & Equity
8
N/A
73
+847%
124
+71%
190
+52%
133
-30%
104
-22%
168
+62%
114
-32%
Shares Outstanding
Common Shares Outstanding
26
26
27
30
30
36
43
44
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett